{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:17:53Z","timestamp":1790637473363,"version":"4.1.0"},"reference-count":34,"publisher":"BMJ","issue":"5","funder":[{"name":"the Natural Science Foundation of Liaoning Province","award":["20180550675"],"award-info":[{"award-number":["20180550675"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Reg Anesth Pain Med"],"accepted":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background and objectives<\/jats:title>\n                  <jats:p>The role of serotonin\u2013norepinephrine reuptake inhibitors (SNRIs) in migraine prophylaxis has not been completely established. Current treatments for vestibular migraine (VM) are based on scarce evidence. We aimed to perform an updated review focusing on the efficacy and tolerability of SNRIs for migraine and VM prevention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the PubMed, Web of Science, and Cochrane Library databases for relevant studies. The primary outcome was migraine frequency. In the case of VM, the Dizziness Handicap Inventory (DHI) scores and Vertigo Severity Scores (VSSs) were extracted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six randomized controlled trials involving 418 patients were analyzed. Patients receiving SNRIs had fewer migraine days than those receiving a placebo (standardized mean difference \u22120.38, 95% CI \u22120.76 to \u22120.01, p=0.04). The effects of SNRIs and other active drugs were comparable. In patients with VM, venlafaxine had a significant advantage over other active drugs in decreasing the VSS (weighted mean difference (MD) \u22121.45, 95%\u2009CI \u22122.11 to \u22120.78, p&lt;0.0001) and the emotional domain score of the DHI (MD \u22122.64, 95%\u2009CI \u22124.97 to \u22120.31, p=0.03). We found no significant difference in the rate of withdrawals due to any reason or withdrawals due to side effects between SNRIs and active drugs and between SNRIs and a placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SNRIs were clinically safe and effective for migraine and VM prophylaxis, were better than a placebo, and not inferior to other active drugs. SNRIs may be a preferable choice for patients with VM with psychiatric disorders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rapm-2019-101207","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T10:29:34Z","timestamp":1584959374000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Serotonin\u2013norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"45","author":[{"given":"Fengzhi","family":"Wang","sequence":"first","affiliation":[{"name":"Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"},{"name":"Neurology, People's Hospital of Liaoning Province, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Cao","sequence":"additional","affiliation":[{"name":"Neurology, People's Hospital of Liaoning Province, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-8479","authenticated-orcid":false,"given":"Zhongxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"2025101110020297000_45.5.323.1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"2025101110020297000_45.5.323.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"2025101110020297000_45.5.323.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30299-5"},{"key":"2025101110020297000_45.5.323.4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/head.13417","article-title":"Anti-Calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American headache Society 60th scientific meeting, San Francisco, June 2018","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"2025101110020297000_45.5.323.5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/0333102416640501","article-title":"Serotonergic mechanisms in the migraine brain - a systematic review","volume":"37","author":"Deen","year":"2017","journal-title":"Cephalalgia"},{"key":"2025101110020297000_45.5.323.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.06.012"},{"key":"2025101110020297000_45.5.323.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112483","article-title":"Analgesic mechanisms of antidepressants for neuropathic pain","volume":"18","author":"Obata","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025101110020297000_45.5.323.8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/head.12205","article-title":"Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study","volume":"53","author":"Young","year":"2013","journal-title":"Headache"},{"key":"2025101110020297000_45.5.323.9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10072-013-1536-0","article-title":"A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine","volume":"35","author":"Engel","year":"2014","journal-title":"Neurol Sci"},{"key":"2025101110020297000_45.5.323.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02185.x"},{"key":"2025101110020297000_45.5.323.11","doi-asserted-by":"publisher","DOI":"10.1017\/S031716710001516X"},{"key":"2025101110020297000_45.5.323.12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237539.09942.06"},{"key":"2025101110020297000_45.5.323.13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-444-63437-5.00003-0","article-title":"Neurotransmitters in the vestibular system","volume":"137","author":"Balaban","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2025101110020297000_45.5.323.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01208.x"},{"key":"2025101110020297000_45.5.323.15","first-page":"1099","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults","volume":"4","author":"Banzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101110020297000_45.5.323.16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/ene.13320","article-title":"Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis","volume":"24","author":"Xu","year":"2017","journal-title":"Eur J Neurol"},{"key":"2025101110020297000_45.5.323.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025101110020297000_45.5.323.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1988.0801001.x"},{"key":"2025101110020297000_45.5.323.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2003.00824.x"},{"key":"2025101110020297000_45.5.323.20","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"2025101110020297000_45.5.323.21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.neurol.2013.05.010","article-title":"Vestibular migraine: diagnostic criteria. consensus document of the Barany Society and the International headache Society","volume":"170","author":"Lempert","year":"2014","journal-title":"Rev Neurol"},{"key":"2025101110020297000_45.5.323.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2004.03.004"},{"key":"2025101110020297000_45.5.323.23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/AJP.0000000000000739","article-title":"Individualization of migraine prevention: a randomized controlled trial of Psychophysical-based prediction of duloxetine efficacy","volume":"35","author":"Kisler","year":"2019","journal-title":"Clin J Pain"},{"key":"2025101110020297000_45.5.323.24","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00524","article-title":"The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine","volume":"8","author":"Liu","year":"2017","journal-title":"Front Neurol"},{"key":"2025101110020297000_45.5.323.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05029.x"},{"key":"2025101110020297000_45.5.323.26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"key":"2025101110020297000_45.5.323.27","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181a8c84f"},{"key":"2025101110020297000_45.5.323.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70272-7"},{"key":"2025101110020297000_45.5.323.29","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"2025101110020297000_45.5.323.30","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial","volume":"271","author":"Lepcha","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2025101110020297000_45.5.323.31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/wnf.0b013e31803bb3ee","article-title":"Effects of valproate on vestibular symptoms and electronystagmographic findings in migraine patients","volume":"30","author":"Celiker","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"2025101110020297000_45.5.323.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307601"},{"key":"2025101110020297000_45.5.323.33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.048926"},{"key":"2025101110020297000_45.5.323.34","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.19"}],"container-title":["Regional Anesthesia &amp; Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2019-101207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:02:10Z","timestamp":1760202130000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2019-101207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,21]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/rapm-2019-101207"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2019-101207","relation":{},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"value":"1098-7339","type":"print"},{"value":"1532-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]}}}